FOR A DTO 1440/A 1 P (4:5-1 DTO/CD/00)	APPLICATION NO.: 10/023,909	ATTY. DOCKET NO.: C1039.70058US00	
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE	FILING DATE: December 18, 2001	CONFIRMATION NO.: 8458	
STATEMENT BY APPLICANT	APPLICANT: Davis et al.		
Sheet OPE of 1	GROUP ART UNIT: 1648	EXAMINER: Jeffrey S. Parkin	
MAR 1 4 2008			

Examiner Initials #	Cis	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue
		Number	Kind Code	Document	of Cited Document MM-DD-YYYY
	A254	7,183,111	B2	Van Nest et al.	02-27-2007
	A255	7,250,403	B2	Van Nest et al.	07-31-2007
	A256	7,271,156	B2	Krieg et al.	07-18-2007
·	A257	2003-0118635	A 1	Dalsgaard et al.	06-23-2003
	A258	2007-0041998	A1	Buschle et al.	02-22-2007
	A259	2007-0224210	A 1	Krieg et al.	09-27-2007
	A260	2007-0232622	Al	Lipford et al.	10-04-2007
	A261	2008-0009455	A9	Krieg et al.	01-10-2008

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	I (book magazine jojirba) serial symbosijim calalog, etc.), date, bagets), volume-issue ilulidents), budiisitel, il	
	C147	ALEXAKIS et al., Microencapsulation of DNA within alginate microspheres and crosslinked chitosan membranes for in vivo application. Appl Biochem Biotechnol. 1995 Jan;50(1):93-106.	
	C148	CULLIS et al., Recent advances in liposome technologies and their applications for systemic gene delivery. Adv Drug Deliv Rev. 1998 Mar 2;30(1-3):73-83. Abstract Only.	
	C149	GOLDBERG et al., Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett. 2000 Jul 3;73(1):13-8.	
	C150	HORNER et al., Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998 Nov 25;190(1):77-82.	
	C151	KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
	C152	MUTWIRI et al., Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol. 2003 Jan 30;91(2):89-103.	
	C153	NORMAN et al., Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000;7:1425-30.	
	C154	WHITMORE et al., LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999;6:1867-75.	

EXAMINER:	/Jeffrey Parkin/	DATE CONSIDERED: 09/05/2008		

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).